Zusammensetzungen zur Behandlung von Fibrose

Details

Veröffentlichungs-Nr.

EP4775207

Anmeldetag

4. Dezember 2019

Veröffentlichung

15. Juli 2026

Rechtsraum

EP

IPC

A61K31/501

Abstract

The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

Anmelder

Firma

Viking Therapeutics, Inc.

Land

🇺🇸 USA